Perrigo Company plc (PRGO) Shareholder Equity
- 2026-06-27: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.54B; Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after TaxUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-22.80M.
- 2026-03-28: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.58B; Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after TaxUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.00M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.61B; Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after TaxUSD $3.30M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $4.80M.
- 2025-09-27: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.64B; Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after TaxUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $69.60M.
Perrigo Company plc Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $0.00 | $6.54B | (m) | $-22.80M | $-4.00B | $2.52B | 3 month · $6.80M | 3 month · $40.10M | (m) | (m) | (m) | (m) |
| 2026-03-28 | $0.00 | $6.58B | (m) | $-3.00M | $-4.08B | $2.50B | 3 month · $14.40M | 3 month · $41.70M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $6.61B | $3.30M | $4.80M | $-3.68B | $2.94B | 12 month · $55.20M | 12 month · $161.80M | (m) | (m) | (m) | (m) |
| 2025-09-27 | $0.00 | $6.64B | (m) | $69.60M | $-2.26B | $4.45B | 3 month · $13.90M | 3 month · $40.70M | (m) | (m) | (m) | (m) |
| 2025-06-28 | $0.00 | $6.66B | (m) | $75.00M | $-2.27B | $4.47B | 3 month · $16.80M | 3 month · $39.80M | (m) | (m) | (m) | (m) |
| 2025-03-29 | $0.00 | $6.69B | (m) | $-70.40M | $-2.26B | $4.36B | 3 month · $11.60M | 3 month · $40.60M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $6.73B | $3.30M | $-162.40M | $-2.25B | $4.32B | 12 month · $64.40M | 12 month · $152.50M | (m) | (m) | (m) | (m) |
| 2024-09-28 | $0.00 | $6.76B | (m) | $9.80M | $-2.21B | $4.57B | 3 month · $16.60M | 3 month · $38.30M | (m) | (m) | (m) | (m) |
| 2024-06-29 | $0.00 | $6.79B | (m) | $-54.20M | $-2.19B | $4.55B | 3 month · $23.40M | 3 month · $38.30M | (m) | (m) | (m) | (m) |
| 2024-03-30 | $0.00 | $6.80B | (m) | $-37.70M | $-2.08B | $4.69B | 3 month · $15.60M | 3 month · $37.60M | $4.69B | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $6.84B | $2.40M | $10.70M | $-2.08B | $4.77B | 12 month · $68.80M | 12 month · $149.70M | $4.77B | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $6.86B | (m) | $-78.10M | $-2.05B | $4.74B | 3 month · $14.70M | 3 month · $38.90M | $4.74B | (m) | (m) | (m) |
| 2023-07-01 | $0.00 | $6.89B | (m) | $19.90M | $-2.06B | $4.85B | 3 month · $18.60M | 3 month · $37.00M | $4.85B | (m) | (m) | (m) |
| 2023-04-01 | $0.00 | $6.91B | (m) | $-6.30M | $-2.07B | $4.83B | 3 month · $24.90M | 3 month · $36.20M | $4.83B | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $6.94B | $-7.10M | $-27.00M | $-2.07B | $4.84B | 12 month · $54.90M | 12 month · $142.40M | $4.84B | (m) | (m) | (m) |
| 2022-10-01 | $0.00 | $6.96B | (m) | $-317.10M | $-2.04B | $4.60B | 3 month · $9.30M | (m) | (m) | (m) | (m) | (m) |
| 2022-07-02 | $0.00 | $6.99B | (m) | $-146.80M | $-1.99B | $4.85B | 3 month · $9.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-04-02 | $0.00 | $7.02B | (m) | $15.00M | $-1.93B | $5.10B | 3 month · $26.30M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $7.04B | $9.90M | $35.50M | $-1.93B | $5.15B | 12 month · $66.90M | (m) | $5.15B | 12 month · $900.00K | (m) | (m) |
| 2021-10-02 | $0.00 | $7.06B | (m) | $54.20M | $-1.94B | $5.18B | 3 month · $18.50M | (m) | (m) | 3 month · $200.00K | (m) | (m) |
| 2021-07-03 | $0.00 | $7.08B | (m) | $307.10M | $-1.88B | $5.51B | 3 month · $13.90M | (m) | (m) | 3 month · $200.00K | (m) | (m) |
| 2021-04-03 | $0.00 | $7.10B | (m) | $276.70M | $-1.82B | $5.56B | 3 month · $24.60M | (m) | (m) | 3 month · $400.00K | (m) | (m) |
| 2020-12-31 | $0.00 | $7.12B | $-11.60M | $395.00M | $-1.86B | $5.66B | 12 month · $56.50M | (m) | $5.66B | 12 month · $2.00M | (m) | (m) |
| 2020-09-26 | $0.00 | $7.30B | (m) | $203.70M | $-1.68B | $5.82B | 3 month · $13.80M | (m) | $5.82B | 3 month · $400.00K | (m) | (m) |
| 2020-06-27 | $0.00 | $7.32B | (m) | $120.70M | $-1.53B | $5.91B | 3 month · $13.10M | (m) | $5.91B | 3 month · $400.00K | (m) | (m) |
| 2020-03-28 | $0.00 | $7.34B | (m) | $35.90M | $-1.59B | $5.79B | 3 month · $15.40M | (m) | $5.79B | 3 month · $800.00K | (m) | (m) |
| 2019-12-31 | $0.00 | $7.36B | $-6.20M | $139.40M | $-1.70B | $5.80B | 12 month · $50.60M | (m) | $5.80B | 12 month · $4.70M | (m) | (m) |
| 2019-09-28 | $0.00 | $7.38B | (m) | $56.60M | $-1.68B | $5.76B | 3 month · $11.90M | (m) | $5.76B | 3 month · $900.00K | (m) | (m) |
| 2019-06-29 | $0.00 | $7.40B | (m) | $99.50M | $-1.77B | $5.73B | 3 month · $14.20M | (m) | $5.73B | 3 month · $1.30M | (m) | (m) |
| 2019-03-30 | $0.00 | $7.41B | (m) | $69.00M | $-1.78B | $5.70B | 3 month · $14.20M | (m) | $5.70B | 3 month · $1.80M | (m) | (m) |
| 2018-12-31 | $0.00 | $7.42B | $-4.40M | $84.60M | $-1.84B | $5.67B | 12 month · $29.60M | (m) | $5.67B | 12 month · $8.10M | (m) | (m) |
| 2018-09-29 | $0.00 | $7.44B | (m) | $143.20M | $-1.92B | $5.66B | 3 month · $3.80M | (m) | $5.66B | 3 month · $500.00K | (m) | (m) |
| 2018-06-30 | $0.00 | $7.59B | (m) | $155.00M | $-1.85B | $5.90B | 3 month · $6.90M | (m) | $5.90B | 3 month · $2.70M | (m) | (m) |
| 2018-03-31 | $0.00 | $7.77B | (m) | $324.30M | $-1.89B | $6.21B | 3 month · $10.00M | (m) | $6.21B | 3 month · $2.70M | (m) | (m) |
| 2017-12-31 | $0.00 | $7.89B | $1.30M | $253.10M | $-1.98B | $6.17B | 12 month · $34.90M | (m) | $6.17B | 12 month · $8.90M | (m) | (m) |
| 2017-09-30 | $0.00 | $7.90B | (m) | $191.20M | $-2.05B | $6.04B | (m) | (m) | $6.04B | (m) | 9 month · $-2.70M | (m) |
| 2017-07-01 | $0.00 | $8.04B | (m) | $130.50M | $-2.09B | $6.08B | (m) | (m) | $6.08B | (m) | 6 month · $-3.40M | (m) |
| 2017-04-01 | $0.00 | $8.12B | (m) | $-26.30M | $-2.02B | $6.07B | (m) | (m) | $6.07B | (m) | 3 month · $-1.70M | (m) |
| 2016-12-31 | $0.00 | $8.13B | $9.50M | $-81.80M | $-2.10B | $5.96B | 12 month · $18.00M | (m) | $5.96B | 12 month · $5.00M | 12 month · $2.00M | (m) |
| 2016-10-01 | $0.00 | $8.15B | (m) | $71.50M | $-736.90M | $7.48B | (m) | (m) | $7.48B | (m) | 9 month · $-1.50M | (m) |
| 2016-07-02 | $0.00 | $8.14B | (m) | $30.70M | $874.30M | $9.05B | (m) | (m) | $9.05B | (m) | 6 month · $100.00K | (m) |
| 2016-04-02 | $0.00 | $8.16B | (m) | $137.40M | $1.43B | $9.73B | (m) | (m) | $9.73B | (m) | 3 month · $-100.00K | (m) |
| 2015-12-31 | $0.00 | $8.14B | $2.90M | $-15.30M | $1.98B | $10.11B | 6 month · $20.30M | (m) | $10.11B | 6 month · $2.50M | 6 month · $-10.30M | (m) |
| 2015-09-26 | $0.00 | $8.63B | (m) | $65.20M | $2.03B | $10.73B | (m) | (m) | $10.73B | (m) | 3 month · $-400.00K | (m) |
| 2015-06-27 | $0.00 | $8.62B | $8.20M | $103.50M | $1.97B | $10.70B | 12 month · $24.70M | (m) | $10.70B | 12 month · $6.90M | 12 month · $-14.90M | (m) |
| 2015-03-28 | $0.00 | $7.70B | (m) | $-19.00M | $1.90B | $9.59B | (m) | (m) | $9.59B | (m) | 9 month · $-3.20M | (m) |
| 2014-12-27 | $0.00 | $7.70B | (m) | $7.40M | $2.01B | $9.72B | (m) | (m) | $9.72B | (m) | 6 month · $-1.50M | (m) |
| 2014-09-27 | $0.00 | $6.69B | (m) | $74.30M | $1.96B | $8.72B | (m) | (m) | $8.72B | (m) | 3 month · $400.00K | (m) |
| 2014-06-28 | $0.00 | $6.68B | $11.90M | $139.60M | $1.90B | $8.72B | 12 month · $18.10M | (m) | $8.72B | 12 month · $6.50M | 12 month · $-13.30M | (m) |
| 2014-03-29 | $0.00 | $6.67B | (m) | $130.30M | $1.76B | $8.56B | (m) | (m) | $8.56B | (m) | 3 month · $-3.80M 9 month · $-100.00K | 3 month · $-5.30M 9 month · $0.00 |
| 2013-12-28 | $0.00 | $6.66B | (m) | $114.60M | $1.72B | $8.50B | (m) | (m) | $8.50B | (m) | 3 month · $-300.00K 6 month · $-100.00K | (m) |
| 2013-09-28 | (m) | $131.00 | (m) | $104.30M | $-190.67K | (m) | (m) | (m) | $-16.70M | (m) | 3 month · $0.00 | (m) |
| 2013-06-29 | $0.00 | $538.50M | (m) | $77.00M | $1.72B | $2.33B | 12 month · $12.30M | (m) | $2.33B | 12 month · $6.10M | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | $39.40M | (m) | $1.85B | 12 month · $14.00M | (m) | (m) | 12 month · $5.00M | (m) | (m) |
| 2011-06-25 | (m) | (m) | (m) | (m) | (m) | $1.53B | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |